View source for Template:Androgen/anabolic steroid dosages for breast cancer

← Template:Androgen/anabolic steroid dosages for breast cancer

You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 3.239.0.0/16 has been blocked by ‪ST47‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider. To prevent abuse, web hosts may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a web host's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: {{unblock|reason=Caught by a web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~}}. You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and they should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 07:37, 6 August 2027. Your current IP address is 3.239.164.172.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
This IP address range has been globally blocked.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

This block affects editing on all Wikimedia wikis.
The IP address or range 3.239.0.0/16 has been globally blocked by ‪Elton‬ for the following reason(s):

Open proxy/Webhost: See the help page if you are affected:

This block will expire on 18:08, 17 February 2029. Your current IP address is 3.239.164.172.

Even while globally blocked, you will usually still be able to edit pages on Meta-Wiki.

If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

Other useful links: Global blocks · Help:I have been blocked

You can view and copy the source of this page:

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="text-align:left; margin-left:auto; margin-right:auto; border:none;"
|+ class="nowrap" | {{Navbar|Androgen/anabolic steroid dosages for breast cancer|mini=y}} <noinclude>[[Androgen]]</noinclude><includeonly>Androgen</includeonly>/<noinclude>[[anabolic steroid]]</noinclude><includeonly>anabolic steroid</includeonly> dosages for <noinclude>[[breast cancer]]</noinclude><includeonly>breast cancer</includeonly>
|-
! Route !! Medication !! Form !! Dosage <noinclude>!! Refs</noinclude>
|-
| rowspan="4" | [[Oral administration|Oral]] || {{No selflink|Methyltestosterone}} || Tablet || 30–200 mg/day <noinclude> || <ref name="Lupulescu1990" /><ref name="Dao1975" /><ref name="Android-Label">{{cite web | title = Android® C-III | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/083976s031lbl.pdf | work = Valeant Pharmaceuticals North America | publisher = U.S. Food and Drug Administration }}</ref><ref name="Ebadi2007">{{cite book| vauthors = Ebadi M |title=Desk Reference of Clinical Pharmacology|url=https://books.google.com/books?id=ihxyHbnj3qYC&pg=PA434|date=31 October 2007|publisher=CRC Press|isbn=978-1-4200-4744-8|pages=434–}}</ref></noinclude>
|-
| {{No selflink|Fluoxymesterone}} || Tablet || 10–40 mg 3x/day <noinclude> || <ref name="Lupulescu1990">{{cite book| vauthors = Lupulescu A |chapter=Hormones and Hormonotherapy|title=Hormones and Vitamins in Cancer Treatment|chapter-url=https://books.google.com/books?id=VddUa-2cp-YC&pg=PA57|date=24 October 1990|publisher=CRC Press|isbn=978-0-8493-5973-6|pages=33–90}}</ref><ref name="Perry2008">{{cite book| vauthors = Perry MC |title=The Chemotherapy Source Book|url=https://books.google.com/books?id=CDADMzS0TKUC&pg=PA369|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-7328-7|pages=369–}}</ref><ref name="Martz2013">{{cite book| vauthors = Martz G |title=Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms|url=https://books.google.com/books?id=8E-qBgAAQBAJ&pg=PA39|date=13 March 2013|publisher=Springer-Verlag|isbn=978-3-642-86282-3|pages=39–}}</ref><ref name="Brotherton1976" /></noinclude>
|-
| {{No selflink|Calusterone}} || Tablet || 40–80 mg 4x/day <noinclude> || <ref name="Lupulescu1990" /><ref name="Brotherton1976" /></noinclude>
|-
|-
| {{No selflink|Normethandrone}} || Tablet || 40 mg/day <noinclude> || <ref name="Dao1975" /></noinclude>
|-
| [[Buccal administration|Buccal]] || {{No selflink|Methyltestosterone}} || Tablet || 25–100 mg/day <noinclude> || <ref name="Ebadi2007" /></noinclude>
|-
| rowspan="10" | [[Injection (medicine)|Injection]] ({{abbrlink|IM|intramuscular injection}} or {{abbrlink|SC|subcutaneous injection}}) || {{No selflink|Testosterone propionate}} || Oil solution || 50–100 mg 3x/week <noinclude> || <ref name="Lupulescu1990" /><ref name="Dao1975">{{cite book | vauthors = Dao TL | chapter = Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms | year = 1975 | pages = 170–192 | doi = 10.1007/978-3-642-65806-8_11 | editor1 = Alan C. Sartorelli | editor2 = David G. Johns | title = Antineoplastic and Immunosuppressive Agents | chapter-url = https://books.google.com/books?id=aU_oCAAAQBAJ&pg=PA170 | isbn = 978-3-642-65806-8}}</ref><ref name="AMA1960">{{cite journal | author = Council on Drugs | year = 1960 | title = Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients | journal = JAMA | volume = 172 | issue = 12 | pages = 1271–83 | doi = 10.1001/jama.1960.03020120049010}}</ref><ref name="Martz2013" /><ref name="Brotherton1976">{{cite book| vauthors = Brotherton J |title=Sex Hormone Pharmacology|url=https://books.google.com/books?id=zt5sAAAAMAAJ|year=1976|publisher=Academic Press|isbn=978-0-12-137250-7|pages=437}}</ref></noinclude>
|-
| {{No selflink|Testosterone enanthate}} || Oil solution || 200–400 mg 1x/2–4&nbsp;weeks <noinclude> || <ref name="Delatestryl-Label">{{cite web | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009165s031lbl.pdf | title = DELATESTRYL® CIII (Testosterone Enanthate Injection, USP) | publisher = U.S Food and Drug Administration }}</ref><ref name="AMA1983">{{cite book|author1=American Medical Association. Division of Drugs|author2=American Society for Clinical Pharmacology and Therapeutics|chapter=Androgens and Anabolic Steroids|pages=913–930|title=AMA Drug Evaluations|url=https://books.google.com/books?id=tsVKAQAAIAAJ|year=1983|publisher=American Medical Association|isbn=978-0-89970-160-8|quote=TESTOSTERONE CYPIONATE [Andro-Cyp, Depo-Testosterone, T-Ionate-P.A.] TESTOSTERONE ENANTHATE [Andryl, Delatestryl] These long-acting, potent esters of testosterone can maintain the testosterone level within the normal range in males for two to four weeks. [...] For metastatic breast carcinoma in women, 200 to 400 mg every two or more weeks.}}</ref></noinclude>
|-
| {{No selflink|Testosterone cypionate}} || Oil solution || 200–400 mg 1x/2–4&nbsp;weeks <noinclude> || <ref name="AMA1983" /><ref name="pmid14182428">{{cite journal | vauthors = Green RB, Sethi RS, Lindner HH | title = Treatment of advanced carcinoma of the breast: Progress in therapy during the past decade | journal = Am. J. Surg. | volume = 108 | pages = 107–21 | date = July 1964 | pmid = 14182428 | doi = 10.1016/0002-9610(64)90094-7 }}</ref></noinclude>
|-
| {{No selflink|Mixed testosterone esters}} || Oil solution || 250 mg 1x/week <noinclude> || <ref name="Martz2013" /></noinclude>
|-
| {{No selflink|Methandriol}} || Aqueous suspension || 100 mg 3x/week <noinclude> || <ref name="AMA1960" /><ref name="pmid14182428" /></noinclude>
|-
| {{No selflink|Androstanolone|Androstanolone ({{Abbr|DHT|dihydrotestosterone}})}} || Aqueous suspension || 300 mg 3x/week <noinclude> || <ref name="Dao1975" /><ref name="AMA1960" /><ref name="SegaloffHorwitt1955">{{cite journal | vauthors = Segaloff A, Horwitt BN, Carabasi RA, Murison PJ, Schlosser JV | title = Hormonal therapy in cancer of the breast. VIII. The effect of dihydrotestosterone (androstanolone) on clinical course and hormonal excretion | journal = Cancer | volume = 8 | issue = 1 | pages = 82–86 | year = 1955 | pmid = 13231036 | doi = 10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R | s2cid = 10089663 }}</ref><ref name="pmid14182428" /></noinclude>
|-
| {{No selflink|Drostanolone propionate}} || Oil solution || 100 mg 1–3x/week <noinclude> || <ref name="Lupulescu1990" /><ref name="Dao1975" /><ref name="Brotherton1976" /></noinclude>
|-
| {{No selflink|Metenolone enanthate}} || Oil solution || 400 mg 3x/week <noinclude> || <ref name="Brotherton1976" /></noinclude>
|-
| {{No selflink|Nandrolone decanoate}} || Oil solution || 50–100 mg 1x/1–3 weeks <noinclude> || <ref name="Deca-Durabolin-Label-AU">{{cite web | title = DECA-DURABOLIN (nandrolone decanoate) | publisher = | url = https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf| archive-url = https://web.archive.org/web/20190309024812/https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf| archive-date = 2019-03-09}}</ref><ref name="Deca-Durabolin-Label-NZ">{{cite web | title = DECA-DURABOLIN | work = New Zealand Data Sheet | url = http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf| archive-url = https://web.archive.org/web/20180128030754/http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf | archive-date = 2018-01-28 }}</ref><ref name="Shorr2007">{{cite book| vauthors = Shorr RI |title=Drugs for the Geriatric Patient E-Book|url=https://books.google.com/books?id=-gmjBQAAQBAJ&pg=PA844|date=11 April 2007|publisher=Elsevier Health Sciences|isbn=978-1-4377-1035-9|pages=844–}}</ref></noinclude>
|-
| {{No selflink|Nandrolone phenylpropionate}} || Oil solution || 50–100 mg/week <noinclude> || <ref name="McKone2013">{{cite book| vauthors = McKone WL |title=Osteopathic Athletic Health Care: Principles and practice|url=https://books.google.com/books?id=2bkACAAAQBAJ&pg=PA125|date=11 November 2013|publisher=Springer|isbn=978-1-4899-3067-5|pages=125–}}</ref><ref name="Brotherton1976" /></noinclude>
|- class="sortbottom"
| colspan="5" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Note:''' Dosages are not necessarily equivalent.<includeonly> '''Sources:''' See template.</includeonly>
|}<!--

--><noinclude>{{Documentation|content=
==See also==
* [[Template:Estrogen dosages for breast cancer]]
* [[Template:Estrogen dosages for prostate cancer]]
* [[Template:Androgen replacement therapy formulations and dosages used in women]]
* [[Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids]]

==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Pages transcluded onto the current version of this page (help):

Androstanolone (edit)
Calusterone (edit)
Drostanolone propionate (edit)
Fluoxymesterone (edit)
Metenolone enanthate (edit)
Methandriol (edit)
Methyltestosterone (edit)
Mixed testosterone esters (edit)
Nandrolone decanoate (edit)
Nandrolone phenylpropionate (edit)
Normethandrone (edit)
Testosterone cypionate (edit)
Testosterone enanthate (edit)
Testosterone propionate (edit)
Template:Abbr (view source) (protected)
Template:Abbrlink (view source) (template editor protected)
Template:Cite book (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Cite web (view source) (protected)
Template:Documentation (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Main other (view source) (protected)
Template:Navbar (view source) (protected)
Template:No self link (view source) (semi-protected)
Template:No selflink (view source) (semi-protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Module:Arguments (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Documentation (view source) (template editor protected)
Module:Documentation/config (view source) (template editor protected)
Module:Documentation/styles.css (view source) (template editor protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Redirect (view source) (protected)
Module:String (view source) (protected)

Return to Template:Androgen/anabolic steroid dosages for breast cancer.

Retrieved from "https://en.wikipedia.org/wiki/Template:Androgen/anabolic_steroid_dosages_for_breast_cancer"